Compositions and methods for preparing factor XA and derivatives

Abstract

The present disclosure relates to protein sequences that can be used to produce Factor Xa proteins and derivatives thereof. The protein sequences include a Factor Xa light chain portion, a heavy chain catalytic domain portion, and an activation peptide C-terminal to the heavy chain catalytic domain portion. It has been discovered that if an activation peptide (AP) is fused to the C-terminal portion of the heavy chain of a Factor Xa protein or derivative, the resulting protein can be expressed more efficiently, and the addition of the activation peptide (AP) to the heavy chain does not affect the activity of the protein.

Description

Technical Field

[0001] Cross - reference to Related Applications This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 62 / 884,652, filed Aug. 8, 2019, and U.S. Provisional Patent Application No. 62 / 990,885, filed Mar. 17, 2020, the entire contents of each of which are hereby incorporated by reference into this disclosure.

Background Art

[0002] Recombinant Factor Xa (fXa) and its derivatives such as andexanet alpha can be produced from host mammalian cell lines. Andexanet alpha (or simply andexanet) is a pharmaceutical product approved in the United States and Europe for patients being treated with rivaroxaban or apixaban when anticoagulation needs to be reversed due to life - threatening or uncontrollable bleeding. Rivaroxaban and apixaban are Factor Xa inhibitors, a group of anticoagulant drugs that also includes betrixaban, edoxaban, and low - molecular - weight heparin (LMWH). Andexanet is a modified recombinant derivative of Factor Xa (fXa). Andexanet acts as a decoy molecule, binds to the inhibitor, reproduces its inhibition of fXa, and thus restores the normal clotting activity of fXa.

[0003] Factor Xa and andexanet have two chains linked by a disulfide bond between the two chains. Recombinant native fXa is typically produced first by the expression of the inactive precursor Factor X (fX), and then by a second step of activating the expressed fX to fXa by a physiological enzyme (e.g., FVIIa / TF, FIXa / FVIIIa) or a non - physiological activating factor (e.g., RVV - X). The difference between fX and fXa lies in the removal of 52 amino acid residues of the activation peptide (AP) at the N - terminus of the fX heavy chain. Since typical production cell lines, such as CHO cells, cannot process and remove the AP, the activation step is necessary to convert inactive fX to native fXa.

[0004] In contrast, andexanet is directly expressed as a fully processed functional molecule that can be purified directly from the collected cell culture medium. This is achieved by replacing the AP sequence in the native fX with the -RKR-tripeptide to form a -RKRRKR-linker between the heavy and light chains, which can be processed by CHO cells. [Overview of the project] [Means for solving the problem]

[0005] This disclosure provides compositions and methods for preparing double-chain activated factor Xa protein or derivatives thereof. It has been found that when an activating peptide (AP) is fused to the C-terminus of the heavy chain of factor Xa protein or derivatives, the resulting protein can be expressed more efficiently, and the addition of the activating peptide (AP) to the heavy chain does not affect the protein's activity. In contrast, adding the activating peptide to other parts of the protein is not useful for enhancing expression (e.g., when added to the C-terminus of the light chain) or further presents manufacturing challenges (e.g., when added to the N-terminus of the heavy chain). Furthermore, contrary to the common knowledge that the removal of the C-terminal 20 amino acid residues (beta-peptide) of the FX heavy chain does not adversely affect factor X protein expression (see, for example, Branchini et al., J Thromb Haemost 2015;13:1468-74 and Ferrarese et al., Thrombosis Res. 2019, 173:4-11), it has been found herein that such a large truncation is undesirable for the efficient expression of fXa and its derivatives. Even more surprisingly, the effect of C-terminal truncation on protein expression can be eliminated by fusing AP to the C-terminus of FXa and its derivatives.

[0006] In one embodiment, the present disclosure is a protein, LC-L1-HC-L2-AP (I) (In the formula, LC contains the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity with SEQ ID NO: 13. L1 is a peptide linker containing a protease recognition site. HC contains the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity with SEQ ID NO: 11. L2 is a peptide linker that is either absent or cannot be processed by a protease, and AP contains an activating peptide. The present invention provides a protein comprising the amino acid sequence of formula (I), wherein, when L1 is treated with a protease, it is possible to produce a double-stranded polypeptide containing LC and HC on separate chains linked by disulfide crosslinks, and the double-stranded polypeptide is capable of binding to a factor Xa inhibitor.

[0007] In another embodiment, a protein, HSA-L2-LC-L1-HC (II) (In the formula, HSA is a variant of human serum albumin (HSA) that has at least 85% sequence identity with HSA. L1 is a peptide linker containing a protease recognition site. L2 is a peptide linker that is either absent or cannot be processed by proteases. LC comprises the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity with SEQ ID NO: 13, and HC contains the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity with SEQ ID NO: 11. A protein is provided which contains the amino acid sequence of formula (II), and when L1 is treated with a protease, it is possible to produce a double-stranded polypeptide containing LC and HC on separate chains, and the double-stranded polypeptide is capable of binding to a factor Xa inhibitor.

[0008] In another embodiment, a protein, LC-L1-HC-L2-HSA (III) (In the formula, HSA is a variant of human serum albumin (HSA) that has at least 85% sequence identity with HSA. L1 is a peptide linker containing a protease recognition site. L2 is a peptide linker that is either absent or cannot be processed by proteases. LC comprises the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity with SEQ ID NO: 13, and HC contains the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity with SEQ ID NO: 11. A protein is provided which contains the amino acid sequence of formula (II), and when L1 is treated with a protease, it is possible to produce a double-stranded polypeptide containing LC and HC on separate chains, and the double-stranded polypeptide is capable of binding to a factor Xa inhibitor.

[0009] In some embodiments, LC does not contain amino acid residues 1-45 of SEQ ID NO: 2. In some embodiments, L2 is absent.

[0010] In some embodiments, a double-chain polypeptide is also provided, comprising a light chain containing the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13, and a heavy chain containing a first fragment containing the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity to SEQ ID NO: 11, and a second fragment located at the C-terminus of the first fragment and containing an activating peptide, wherein the double-chain polypeptide is capable of binding to a factor Xa inhibitor.

[0011] A double-stranded polypeptide comprising a first fragment comprising human serum albumin (HSA) or a variant having at least 85% sequence identity to HSA and a second fragment comprising the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity to SEQ ID NO: 11, which is capable of binding to factor Xa inhibitor, and the light chain does not include amino acid residues 1 to 45 of SEQ ID NO: 2, and a double-stranded polypeptide is also provided.

[0012] Polynucleotides, cells transfected with polynucleotides and methods are also provided in some embodiments for preparing double-stranded polypeptides.

Brief Description of the Drawings

[0013] [Figure 1] Shows the structures of constructs C01 to C14. [Figure 2A] Shows the results of expression and activity tests for C05, C007, C08 and C10. [Figure 2B] Same as above. [Figure 2C] Same as above. [Figure 2D] Same as above. [Figure 3] Shows the results of expression and activity tests for C12 to C14 using andexanet precursor (AnXa), C08 and C10 as references.

Modes for Carrying Out the Invention

[0014] I. Definitions All numerical specifications, including ranges, for example pH, temperature, time, concentration, and molecular weight, are approximate values that vary by 0.1 increments in either the (+) or (-) direction. Although not always explicitly stated, it should be understood that the term "about" is placed before all numerical specifications. Although not always explicitly stated, it should also be understood that the reagents described herein are merely exemplary, and equivalents of such reagents are known in the art.

[0015] The terms "protein" and "polypeptide" are used interchangeably and refer to compounds, in the broadest sense, of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits can be linked by peptide bonds. In another embodiment, the subunits can be linked by other bonds, such as esters, ethers, etc. A protein or peptide must contain at least two amino acids, and there is no set limit to the maximum number of amino acids that can be included in the sequence of the protein or peptide. As used herein, the term "amino acid" refers to natural and / or non-natural or synthetic amino acids, including glycine and both D and L optical isomers, amino acid analogs, and peptidomimetics. The one-letter and three-letter abbreviations for the naturally occurring amino acids are shown below. Peptides of three or more amino acids are generally called oligopeptides when the peptide chain is short. When the peptide chain is long, the peptide is generally called a polypeptide or protein.

[0016] "Factor Xa," ​​or "fXa," or "fXa protein" refers to a serine protease in the blood coagulation pathway produced from inactive factor X (fX). Factor Xa is activated either by factor IXa together with its cofactor, factor VIIIa, in the complex known as the intrinsic Xase, or by factor VIIa together with its cofactor, tissue factor, in the complex known as the extrinsic Xase. fXa forms a membrane-bound prothrombinase complex with factor Va, and is the active ingredient in the prothrombinase complex that catalyzes the conversion of prothrombin to thrombin. Thrombin is an enzyme that catalyzes the conversion of fibrinogen to fibrin, which ultimately leads to blood clot formation. Therefore, the biological activity of fXa is sometimes referred to herein as "procoagulant activity."

[0017] Factor Xa is a double-stranded molecule linked by a single disulfide bond between the two chains. The light chain (LC) has 139 amino acid residues (amino acids 1-139 in SEQ ID NO: 2) and contains a γ-carboxyglutamic acid (Gla) rich domain (amino acids 1-45 in SEQ ID NO: 2) with a short aromatic stack (AS) (amino acids 40-45 in SEQ ID NO: 2), followed by two epidermal growth factor (EGF)-like domains (EGF1: amino acids 46-84 in SEQ ID NO: 2, EGF2: amino acids 85-128).

[0018] The pre-activation heavy chain (HC) has 306 amino acids and contains a 52-amino acid activated peptide (AP: amino acids 143-194 in SEQ ID NO: 2), followed by a catalytic domain (amino acids 195-448 in SEQ ID NO: 2). The catalytic three-residue equivalent for chymotrypsin number H57-D102-S195 is located at His236, Asp282, and Ser379 in the fX sequence (SEQ ID NO: 2) (amino acids 236, 282, and 379 in SEQ ID NO: 2). The heavy chain contains a serine protease, a trypsin-like active site, and a glycosylated N-terminal activated peptide. The heavy chain has at least three forms, α, β, and γ, which are distinguished by cleavage of the C-terminal peptide in the heavy chain.

[0019] The nucleotide sequence encoding human factor X ("fX") can be found in GenBank, "NM_000504". The corresponding amino acid sequence and domain structure of fX are described in Leytus et al, Biochemistry, 1986, 25:5098-5102. The domain structure of mature fX is also described in Venkateswarlu, D. et al, Biophysical Journal, 2002, 82:1190-1206. Simultaneously with catalytic cleavage of the first 52 residues of the heavy chain, fX is activated to fXa (SEQ ID NO: 3). FXa contains a light chain and a heavy chain in which the glutamate residues become gamma-carboxyglutamate after translation. The first 45 amino acid residues of the light chain contain 11 post-translational modified γ-carboxyglutamate residues (Gla), and are therefore called the Gla domain. The Gla domain also contains a short (6 amino acid residue) aromatic stack sequence. Chymotrypsin digestion selectively removes 1–44 residues, resulting in fXa lacking the Gla domain. The serine protease catalytic domain of fXa is located in the C-terminal heavy chain. The heavy chain of fXa is highly homologous to other serine proteases such as thrombin, trypsin, and activated protein C.

[0020] [Table 1]

[0021] [Table 2]

[0022] [Table 3]

[0023] "Natural fXa" or "wild-type fXa" refers to fXa that is naturally present in plasma or isolated in its original, unmodified form, and which has the biological activity to activate prothrombin, thereby promoting blood clot formation. This term includes naturally occurring polypeptides isolated from tissue samples and recombinantly produced fXa. "Activated fXa" refers to fXa that has the biological activity to activate prothrombin. "Activated fXa" may be natural fXa or modified fXa that retains procoagulant activity.

[0024] "fXa derivative," "modified fXa," or "derivative of factor Xa protein" refers to an fXa protein that has been modified but can still directly or indirectly bind to a factor Xa inhibitor.

[0025] The derivatives may have a modified active site and / or a modified Gla domain. Further modifications are also conceivable. Such modifications are conceivable to be made by one or more of the following means: deletion of one or more amino acids from the sequence, substitution of one or more amino acid residues with one or more different amino acid residues, and / or manipulation of one or more amino acid side chains or their C or N terminus.

[0026] The term "active site" refers to a portion of an enzyme or antibody where a chemical reaction occurs. A "modified active site" is a structurally modified active site that provides increased or decreased chemical reactivity or specificity. An active site is assumed to include not only the actual site but also the domain containing the active site. Examples of active sites include, but are not limited to, the catalytic domain of human factor X containing 235–488 amino acid residues and the catalytic domain of human factor Xa containing 195–488 amino acid residues. The catalytic tri-residue equivalent for chymotrypsin number H57-D102-S195 is located at His236, Asp282, and Ser379. Examples of modified active sites include, but are not limited to, individual or combined catalytic tri-residues. One modification relates to an fXa derivative having the modified active site Ser379Ala. Additional examples include modifications to the catalytic domain of human factor Xa, comprising 195–448 amino acid residues, by at least one amino acid substitution at positions Arg306, Glu310, Arg347, Lys351, Lys414, or Arg424.

[0027] The term "factor Xa inhibitor" or "inhibitor of factor Xa" refers to a compound that can directly or indirectly inhibit the activity of coagulation factor Xa, which catalyzes the conversion of prothrombin to thrombin, in vitro and / or in vivo. Known examples of fXa inhibitors, without limitation, include edoxaban, fondaparinux, hydraparinux, biotinylated hydraparinux, enoxaparin, Fragmin, NAP-5, rNAPc2, tissue factor pathway inhibitors, DX-9065a (e.g., Herbert, JM, et al, J Pharmacol Exp Ther. 1996 276(3):1030-8), YM-60828 (e.g., Taniuchi, Y., et al, Thromb Haemost. 1998 79(3):543-8), YM-150 (e.g., Eriksson, BI et al, Blood 2005;106(11), Abstract 1865), apixaban, rivaroxaban, and PD-348292 (e.g., Pipeline Insight: Antithrombotics-Reaching This includes otamixaban, razakixaban (DPC906), BAY59-7939 (e.g., Turpie, AG, et al, J. Thromb. Haemost. 2005, 3(11):2479-86), edoxaban (e.g., Hylek EM, Curr Opin Invest Drugs 2007 8(9):778-783), LY517717 (e.g., Agnelli, G., et al, J. Thromb. Haemost. 2007 5(4):746-53), GSK913893, betrixaban and its derivatives. Low molecular weight heparin ("LMWH") is also considered a factor Xa inhibitor.

[0028] In one embodiment, the derivatives of the present invention bind directly or indirectly to factor Xa inhibitors. The terms “binding,” “binding,” “recognizing,” or “recognizing” mean, as used herein, to include intermolecular interactions that can be detected, for example, by hybridization assays. The term also means to include intermolecular “binding” interactions. Interactions may be, for example, essentially protein-protein, protein-nucleic acid, protein-small molecule, or small molecule-nucleic acid. Binding may be “direct” or “indirect.” “Direct” binding includes direct physical contact between molecules. “Indirect” binding includes molecules that simultaneously have direct physical contact with one or more intermediate molecules. For example, the derivatives of the present invention are envisioned to indirectly bind to and substantially neutralize low molecular weight heparin and other indirect inhibitors of factor Xa. This binding may result in the formation of a “complex” containing the interacting molecules. “Complex” refers to the binding of two or more molecules joined together by covalent or non-covalent binding, interaction, or force.

[0029] The terms “neutralize,” “counteract,” or “reaction” to the activity of an fXa inhibitor, or similar phrases, refer to inhibiting or blocking the factor Xa inhibitory or anticoagulant function of the fXa inhibitor. Such phrases refer to partial or complete inhibition or blocking of the function of the fXa inhibitor activity in vitro and / or in vivo. These terms also refer to the neutralization effect of at least about 20% of fXa inhibitor-dependent pharmacological or surrogate markers. Examples of markers include, but are not limited to, INR, PR, aPTT, ACT, anti-fXa units, thrombin generation (Technothrombin TGA), thromboelastography, CAT (automated calibrated thrombogram), and other similar markers.

[0030] "Composition" is intended to mean a combination of other compounds or compositions, such as activators and adjuvants, that are either inert (e.g., detectable active substances or labels) or active.

[0031] A "pharmaceutical composition" comprises a combination of an inactive or active carrier and an activator, and is intended to make the composition suitable for diagnostic or therapeutic use in vitro, in vivo, or ex vivo.

[0032] As used herein, the term “its equivalent” refers to a reference protein, polypeptide, or nucleic acid that possesses only minimal homology but still maintains the desired functionality. Any modified protein referred to herein is assumed to include its equivalent. For example, homology may be at least 75% homology, instead at least 80%, or instead at least 85%, or instead at least 90%, or instead at least 95%, or instead 98%, and can exhibit substantially equivalent biological activity to the reference polypeptide or protein. The “sequence identity” of a polynucleotide or polynucleotide region (or polypeptide or polypeptide region) to another sequence (e.g., 80%, 85%, 90%, or 95%) means that, when aligned, that percentage of bases (or amino acids) are the same when comparing the two sequences. It should be noted that when only the heavy chain of fXa (or related serine protease) is used, the overall homology may be lower than 75%, such as 65% or 50%, but the desired functionality may still be present.

[0033] The "sequence identity" of a polynucleotide or polynucleotide region (or polypeptide or polypeptide region) with respect to another sequence of a certain percentage (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) means that, when aligned, that percentage of bases (or amino acids) will be the same when comparing the two sequences.

[0034] II. Preparation of Factor Xa and its Derivatives Andexanet alpha, or simply Andexanet, is a modified factor Xa polypeptide approved in the United States and Europe for use in patients treated with rivaroxaban or apixaban when anticoagulation is required due to life-threatening or uncontrolled bleeding. Also known as r-Antidote, the structure and activity of Andexanet are described in U.S. Patent No. 8,153,590.

[0035] Andexanet is the processed product of the processed double-stranded polypeptide, SEQ ID NO: 4, after cleavage of the -RKRRKR-(SEQ ID NO: 7) linker. Andexanet is represented by SEQ ID NO: 5, which includes a light chain (SEQ ID NO: 6) and a heavy chain (SEQ ID NO: 8). The light and heavy chains are linked by a single disulfide bond between cysteine ​​98 (Cys98) of the light chain and cysteine ​​108 (Cys108) of the heavy chain. Like wild-type fXa, in a certain production unit, andexanet undergoes post-translational modification, resulting in glycosylation at certain amino acid residues, such as Ser56, Ser72, Ser76 and Thr82 of the light chain and Thr249 of the heavy chain, and a modification residue (3R)-3-hydroxyAsp at Asp29 of the light chain. Furthermore, in addition to interchain disulfide bonds, intrachain disulfide bonds may be formed between cysteine ​​16 and 27, 21 and 36, 38 and 47, 55 and 66, 62 and 75, and 77 and 90 of the light chain, and between cysteine ​​7 and 12, 27 and 43, 156 and 170, and 181 and 209 of the heavy chain.

[0036] [Table 4]

[0037] [Table 5]

[0038] The precursor of andexanet (SEQ ID NO: 4) contains three mutations compared to wild-type fXa. The first mutation is a deletion of 6-39aa in the Gla domain of fX. The second mutation is a substitution of the activation peptide sequence 143-194aa by -RKR-. This produces the -RKRRKR- (SEQ ID NO: 7) linker that connects the light and heavy chains. Simultaneously with secretion, this linker is cleaved, resulting in a double-stranded polypeptide (andexanet). The third mutation is a mutation of the active site residue S379 to an Ala residue.

[0039] These structural changes mean that andexanets do not compete with fXa when they aggregate to form prothrombinase complexes, resulting in reduced or absent catalytic activity. Therefore, andexanets can capture circulating fXa inhibitors without interfering with the intrinsic coagulation mechanism. Similar antidotes have also been disclosed, including those with further deletions in the EGF-1 or EGF-2 domains.

[0040] Sequence ID 4 is a precursor protein expressed in host cells to produce an andexanet, which can be digested by endogenous or supertransfected furin proteins targeting the -RKRRKR-linker (Sequence ID 7). The activating peptide (AP) derived from wild-type fX was considered unnecessary, as it was replaced with the artificial -RKRRKR-linker.

[0041] However, it has been found herein that AP inclusion can increase the expression of the treated double-chain product. However, AP inclusion in the precursor protein, such as at the N-terminus of the heavy chain, presents challenges in production. Protein production is typically carried out by CHO cells, which do not have the enzymatic activity to spontaneously process factor X at the cleavage site -LTR- between AP and the N-terminus of the heavy chain (SEQ ID NO: 2). Therefore, fXa derivatives contain specific linkers that recognize the -RKR- and -RKRRKR- (SEQ ID NO: 7) linkers and can be cleaved by endogenous furin in CHO cells or by a concurrently transfected furin protease.

[0042] In this regard, it was found that when AP is attached to the protein via a furin-recognizable linker (e.g., C04-C06), furin may process the linker too quickly, thwarting the objective of increasing expression. In addition, if the furin-recognizable linker is not properly processed, the processed double-stranded molecule may become inactive. On the other hand, when AP is fused to the light chain in a way that prevents cleavage (e.g., C07), it does not have the ability to increase protein expression. AP was most effective in increasing protein expression and functional activity only when fused to the C-terminus of the heavy chain in a way that prevents cleavage.

[0043] It was further discovered that deletion of 13 or 15 C-terminal amino acid residues of the heavy chain (Delta HC-13 and Delta HC-15, respectively) had no significant effect on protein expression or activity. In contrast, deletion of 20 C-terminal amino acid residues from the C-terminus of HC (Delta HC-20) significantly reduced protein expression. This was unexpected given the general knowledge that truncating native FX to 20 amino acid residues did not significantly affect factor X expression, as demonstrated, for example, in Branchini et al., Journal of Thrombosis and Haemostasis, 13:1468-1474 (2015). Even more surprisingly, fusing AP to the C-terminus of FXa and its derivatives eliminated the effect of C-terminal truncation on protein expression.

[0044] According to one embodiment of the present disclosure, therefore, formula (I): LC-L1-HC-L2-AP (I) A precursor protein containing the sequence is provided.

[0045] Here, LC represents a biological equivalent such as a protein fragment containing the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13. HC represents a biological equivalent such as a protein fragment containing the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity to SEQ ID NO: 11. In some embodiments, L2 contains at least the first 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues of the beta peptide (RGLPKAKSHAPEVITSSPLK, SEQ ID NO: 38).

[0046] L1 represents a protein linker containing a protease recognition site. In some embodiments, the protease may be furin. L2, on the other hand, may be null (in other words, optional) or a peptide linker. However, if L2 is a linker, L2 cannot be processed by the protease. Therefore, when a protein is incubated with a protease, the protease can digest the protein and produce a double-stranded polypeptide, one containing LC and the other containing HC-L2-AP. In some embodiments, the produced double-stranded polypeptide can bind to a factor Xa inhibitor.

[0047] Interestingly, in the first set of experiments, the expression-enhancing effect of AP was not observed with human serum albumin (HSA), a protein commonly used to enhance the expression or stability of expressed proteins. See C10 in Example 2. However, in further experiments (Example 3), two precursor constructs, C13 and C14, in which HSA was fused to the N-terminus of the light chain, exhibited significantly improved expression and activity. Therefore, it is hypothesized that the complete deletion of the Gla domain (C10 had a partial deletion of the Gla domain) enhanced the effect of HSA. In other words, the expression-enhancing effect of HSA was more pronounced when HSA was directly fused to the EGF1 domain.

[0048] According to another embodiment of this disclosure, therefore, formula (II): HSA-L2-LC-L1-HC (II) A precursor protein containing the sequence is provided.

[0049] In another embodiment, formula (III): LC-L1-HC-L2-HSA (III) A precursor protein containing the sequence is also provided.

[0050] Here, HSA represents human serum albumin (HSA) or a variant having at least 85% sequence identity to HSA, L1 is a peptide linker containing a protease recognition site, L2 is a peptide linker that is absent or cannot be treated by a protease, LC contains the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13, and HC contains the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity to SEQ ID NO: 11. When L1 is treated by a protease, the protein of formula (II) produces a double-stranded polypeptide containing LC and HC on separate chains, and the double-stranded polypeptide is capable of binding to a factor Xa inhibitor. In some embodiments, LC does not contain amino acid residues 1-45 of SEQ ID NO: 2. In some embodiments, L2 is absent.

[0051] In some embodiments, the protein of formula (I) may further contain HSA fused to the N-terminus of the light chain or the C-terminus of the heavy chain. In some embodiments, the protein of formula (II) may further contain AP fused to the C-terminus of the heavy chain. In some embodiments, the protein of formula (III) may further contain AP fused to the N-terminus of the light chain.

[0052] In some embodiments, any protein of this disclosure may be fused to an Fc fragment of an immunoglobulin. The crystalline fragment region (Fc region) is the tail region of an antibody that interacts with cell surface receptors called Fc receptors and several proteins of the complement system. In IgG, IgA, and IgD antibody isotypes, the Fc region consists of two identical protein fragments derived from the second and third constant domains of the two heavy chains of the antibody.

[0053] In some embodiments, the Fc fragment used is an IgG Fc fragment such as IgG1, IgG2, or IgG4. In some embodiments, the Fc fragment further includes a CH1 region in addition to the CH2 and CH3 regions. Example Fc fragment sequences are provided in Table 24, SEQ ID NO: 46. In some embodiments, the fusion protein includes a signal peptide such as SEQ ID NOs: 34-36 or 45.

[0054] In some embodiments, only one chain of the Fc fragment is fused to the fXa derivative. In some embodiments, both chains of the Fc fragment are fused to the fXa derivative.

[0055] The terms “furin” or “basic amino acid cleavage enzyme” refer, as used herein, to a protein having an amino acid sequence substantially identical to one of the representative furin sequences of GenBank acceptance number NP_002560 (human), NP_001074923 (mouse), or NP_062204 (rat). Suitable cDNA encoding furin is provided under GenBank acceptance number NM_002569 (human), NM_001081454 (mouse), or NM_019331 (rat). In certain embodiments, furin refers to human furin.

[0056] Human serum albumin (HSA) is serum albumin found in the blood of humans. HSA makes up about half of serum proteins. HSA is produced in the liver and is water-soluble. Among its other functions, albumin transports hormones, fatty acids and other compounds, regulates pH, and maintains colloid osmotic pressure. Albumin is synthesized in the liver as preproalbumin, which has an N-terminal peptide that is removed before the nascent protein is released from the rough endoplasmic reticulum. This product, proalbumin, is then cleaved in the Golgi vesicles to produce secretory albumin. HSA may have a native sequence or, as tested herein, may have a single Cys34Ser mutation (SEQ ID NO: 15) to remove free cysteine ​​in native HSA.

[0057] AP represents a protein fragment containing an activating peptide. An "activating peptide" is a peptide that is covalently or noncovalently attached to a protein and keeps the protein inactive until the activating peptide is removed. In some embodiments, the activating peptide contains four or more glycosylation sites. Amino acid residues such as Asp, Ser, Tyr, and Thr are known to be suitable glycosylation sites. In some embodiments, AP is 10 to 100 amino acid residues long (or 10 to 80, 15 to 70, 20 to 60, or 10 to 50 amino acid residues instead) and contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 glycosylation sites.

[0058] Activating peptides are present in wild-type proteins such as factor IX (fIX), factor X (fX), factor XIII (fXIIII), factor II (prothrombin), and the precursor of protein C. Their respective sequences are shown in Table 6.

[0059] [Table 6]

[0060] In some embodiments, the activating peptide includes the amino acid sequence of SEQ ID NOs: 12, 31, 32, 33, 39, or 40, or includes an amino acid sequence having at least 85% sequence identity to SEQ ID NOs: 12, 31, 32, 33, 39, or 40. In some embodiments, the activating peptide includes an amino acid sequence having at least 85% sequence identity to SEQ ID NOs: 12, or alternatively at least 70%, 75%, 80%, 90%, 95%, 98%, or 99%. In some embodiments, the activating peptide includes an amino acid sequence derived from SEQ ID NOs: 12, having one, two, or three amino acid additions, deletions, and / or substitutions. In some embodiments, the activating peptide includes an amino acid sequence having at least 85% sequence identity to SEQ ID NOs: 31, or alternatively at least 70%, 75%, 80%, 90%, 95%, 98%, or 99%. In some embodiments, the activating peptide includes an amino acid sequence derived from SEQ ID NOs: 31, having one, two, or three amino acid additions, deletions, and / or substitutions. In some embodiments, the activating peptide includes an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO: 32. In some embodiments, the activating peptide includes an amino acid sequence derived from SEQ ID NO: 32, having one, two, or three amino acid additions, deletions, and / or substitutions. In some embodiments, the activating peptide includes an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO: 33. In some embodiments, the activating peptide includes an amino acid sequence derived from SEQ ID NO: 33, having one, two, or three amino acid additions, deletions, and / or substitutions. In some embodiments, the activating peptide includes an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO: 39. In some embodiments, the activated peptide comprises an amino acid sequence derived from SEQ ID NO: 39, having one, two, or three amino acid additions, deletions, and / or substitutions.In some embodiments, the activating peptide comprises an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity with respect to SEQ ID NO: 40. In some embodiments, the activating peptide comprises an amino acid sequence derived from SEQ ID NO: 40, having 1, 2, or 3 amino acid additions, deletions, and / or substitutions. In some embodiments, the activating peptide is 10 to 100 amino acid residues in length (or 10 to 80, 15 to 70, 20 to 60, or 10 to 50 amino acid residues in length) and comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 glycosylation sites.

[0061] In some embodiments, the protease is furin, but other proteases, such as other proprotein convertases like PC5, or coagulation enzymes like FXa and thrombin are also within the scope of this disclosure. Examples of peptide linkers suitable for furin include -RKR- and -RKRRKR- (SEQ ID NO: 7).

[0062] As described, in some embodiments, L2 is absent (null). In some embodiments, L2 is a peptide linker having a length of 1 to 50 (or 1 to 40, 1 to 30, 1 to 25, 1 to 20, 5 to 40, 10 to 30, 15 to 35) amino acid residues. The peptide linker is preferably mobile and has at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% Gly and / or Ser.

[0063] The produced double-stranded polypeptide is suitable in some embodiments for use as an antidote to fXa factor inhibitor-based anticoagulant therapy. In some embodiments, the double-stranded polypeptide is unable to compete with fXa for aggregation into a prothrombinase complex, has a reduced ability to aggregate into a prothrombin complex, or is unable to aggregate into a prothrombin complex. A functional Gla domain is required for aggregation into a prothrombin complex. In some embodiments, LC does not contain substantial portions of the Gla domain, such as amino acids 6-39 of SEQ ID NO: 2. In some embodiments, LC does not contain amino acids 1-45 of SEQ ID NO: 2.

[0064] In some embodiments, LC comprises the amino acid sequence of SEQ ID NO: 6, or comprises an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity to SEQ ID NO: 6.

[0065] In some embodiments, the LC comprises an amino acid sequence having at least 85% sequence identity to the entire light chain sequence of wild-type fXa (i.e., amino acid residues 1-139 of SEQ ID NO: 3) or to the full-length light chain sequence of wild-type fXa, or alternatively, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity.

[0066] The resulting double-chain polypeptide exhibits reduced catalytic activity compared to wild-type human factor Xa in some embodiments. This can be achieved, for example, by mutations in one or more active sites in the heavy chain, such as His236, Asp282, and Ser379 (amino acids 236, 282, and 379 of SEQ ID NO: 2).

[0067] In some embodiments, HC includes at least the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO: 10. In some embodiments, HC includes at least the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO: 11. In some embodiments, HC includes the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO: 7.

[0068] In some embodiments, HC comprises the full heavy chain sequence of wild-type fXa (i.e., amino acid residues 140-393 of SEQ ID NO: 3) or comprises an amino acid sequence having at least 85% or, instead, at least 70%, 75%, 80%, 90%, 95%, 98%, or 99% sequence identity with respect to the full heavy chain sequence of wild-type fXa.

[0069] In some embodiments, the protein (or HC) does not contain the 13C-terminal amino acid residues of the heavy chain (436-448 in SEQ ID NO: 2). In some embodiments, the protein (or HC) does not contain the 15C-terminal amino acid residues of the heavy chain (434-448 in SEQ ID NO: 2).

[0070] Non-restrictive examples of protein sequences include SEQ ID NOs. 25 and 26.

[0071] In some embodiments, the signal peptide (or combined with a propeptide) is located at the N-terminus of the protein. Examples of signal / propeptides are shown in Table 7.

[0072] [Table 7]

[0073] The disclosed precursor protein may have the same amino acid residues as wild-type fX, except for the indicated deletion. In preferred embodiments, specific amino acid substitutions, such as the Ser379Ala substitution shown in SEQ ID NO: 4, are introduced to lead to the production of an effective antidote against fXa inhibitors. In some embodiments, the precursor protein may produce a double-stranded polypeptide capable of binding to factor Xa inhibitors when L1 and L2 are digested. When amino acid substitutions are introduced, in some embodiments, the digested double-stranded polypeptide may be unable to compete with fXa for aggregation into a prothrombinase complex, have a reduced ability to aggregate into a prothrombin complex, or be unable to aggregate into a prothrombinase complex and / or have reduced catalytic activity compared to wild-type human factor Xa.

[0074] In some embodiments, double-stranded polypeptides that can be obtained by processing the precursor proteins of the present disclosure are also provided. In one embodiment, a double-stranded polypeptide is provided that is capable of binding to a factor Xa inhibitor, comprising a light chain containing the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13, a first fragment containing the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity to SEQ ID NO: 11, and a heavy chain containing a second fragment located at the C-terminus of the first fragment and containing an activating peptide. Examples of such double-stranded polypeptides are provided in Tables 8 and 9 below.

[0075] [Table 8]

[0076] [Table 9]

[0077] Polynucleotides and host cells This disclosure also provides host cells containing polynucleotides encoding the disclosed proteins and one or more polypeptides. In one embodiment, the polypeptides are expressed and present on the cell surface (extracellularly). Suitable cells containing the polypeptides of the present invention include, but are not limited to, bacterial cells, yeast cells, insect cells, animal cells, mammalian cells, mouse cells, rat cells, sheep cells, monkey cells and human cells, as well as prokaryotic and eukaryotic cells. Examples of bacterial cells include Escherichia coli, Salmonella enterica and Streptococcus gordonii. Cells can be purchased from private vendors such as the American Type Culture Collection (ATCC, Rockville Maryland, USA) or cultured from isolates using methods known in the art. Suitable eukaryotic cell examples include, but are not limited to, 293T HEK cells and hamster cell lines named CHO, BHK-21; mouse cell lines named NIH3T3, NS0, and C127; monkey cell lines COS and Vero; and human cell lines HeLa, PER.C6 (commercially available from Crucell), U-937, and Hep G2. Non-limited examples of insect cells include the armyworm (Spodoptera frugiperda). Examples of yeasts useful for expression include, but are not limited to, the genera Saccharomyces, Schizosaccharomyces, Hansenula, Candida, Torulopsis, Yarrowia, or Pichia. See U.S. Patent Nos. 4,812,405; 4,818,700; 4,929,555; 5,736,383; 5,955,349; 5,888,768 and 6,258,559.

[0078] In some embodiments, host cells are further transfected with polynucleotides encoding furin proteins.

[0079] In addition to species specificity, the cells may be of any particular tissue type, such as neurons, or somatic or embryonic stem cells, such as embryonic stem cells, adipose stem cells, neuronal stem cells, and hematopoietic stem cells, which may or may not be able to differentiate into neuronal cells. The stem cells may originate from humans or animals, such as mammals. [Examples]

[0080] The present invention will be further understood by reference to the following embodiments, which are intended to be purely illustrative of the invention. The present invention is not limited in scope by the exemplary embodiments, and the embodiments are intended to illustrate only one aspect of the invention. Any functionally equivalent method is within the scope of the invention. Various modifications of the invention will be apparent to those skilled in the art from the foregoing description and the accompanying drawings, in addition to the modifications described herein. Such modifications fall within the scope of the appended claims.

[0081] Example 1. Preparation of expression vector This embodiment generated polynucleotide constructs encoding precursor proteins that can be used to produce factor Xa derivatives containing andexanets, which can be used to neutralize factor Xa inhibitors. The precursor protein sequences are shown in Tables 10-20 and Figure 1, and are denoted as C01-C11.

[0082] Compared to the precursor of andexanet (SEQ ID NO: 4), C01 (SEQ ID NO: 18) contained a deletion of the 20C-terminal amino acid residue in the heavy chain. Similarly, C02 (SEQ ID NO: 19) and C03 (SEQ ID NO: 20) contained deletions of the 13C-terminal amino acid residues and the 15C-terminal amino acid residues, respectively.

[0083] Using C03 as a reference, factor Xa-activating peptide (AP) was added back into precursor C04 (SEQ ID NO: 21). Unlike wild-type fX, a -RKRRKR-linker was placed between AP and the heavy chain to facilitate furin treatment (similar to wild-type fX, the -RKR-linker was also present between the light chain and AP). Another version of this precursor, C05 (SEQ ID NO: 22), was also prepared, which lacked the C-terminal truncation but had the N-terminal 11 amino acids of the light chain removed. Yet another precursor, C06 (SEQ ID NO: 23), was also prepared, containing both the N-terminal 11 amino acid truncation and the C-terminal 15 amino acid truncation. In C07 (SEQ ID NO: 24), the native -RKR-linker between the light chain and AP was removed.

[0084] In precursors C08 (SEQ ID NO: 25) and C09 (SEQ ID NO: 26), AP was placed at the C-terminus of the heavy chain. In C08, AP fused directly to the heavy chain, while in C09, it fused via an artificial linker (-KSS(GSS)9GSS-, SEQ ID NO: 14).

[0085] In precursors C10 (SEQ ID NO: 27) and C11 (SEQ ID NO: 28), human serum albumin (HSA, SEQ ID NO: 15) was fused to either the N-terminus or C-terminus, and the HSA may have a native sequence or a sequence with a single Cys34Ser mutation (SEQ ID NO: 15) to remove free cysteine ​​from the native HSA. In C10, the heavy chain was intact, and in C11, the heavy chain had a 15-amino acid truncation at the C-terminus.

[0086] [Table 10]

[0087] [Table 11]

[0088] [Table 12]

[0089] [Table 13]

[0090] [Table 14]

[0091] [Table 15]

[0092] [Table 16]

[0093] [Table 17]

[0094] [Table 18]

[0095] [Table 19]

[0096] [Table 20]

[0097] Novel polynucleotides encoding these precursor proteins (containing suitable signal peptides) were synthesized. After validating these polynucleotide sequences, they were ligated into expression vectors suitable for transfection into mammalian host cells. An example expression vector was the AB1 vector. Another expression vector used was the pcDNA3.3 vector (Thermo Fisher Scientific).

[0098] The expression vectors were transfected into host cells CHO-DUXB11, CHO-S (Thermo Fisher Scientific), ExpiCHO-S (Thermo Fisher Scientific), DG44 (Thermo Fisher Scientific), or CHO-M. Transfection was performed using the ExpiFectamine® CHO transfection kit (Thermo Fisher Scientific) or electroporation with reagents and an electroporator (Maxcyte), according to the product's recommendations.

[0099] Transfected CHO cells were cultured in shaking flasks, and protein expression was monitored over time. Protein expression was monitored transiently without prior antibiotic use for stable cell selection. Protein expression was further monitored using a stable CHO cell pool. The stable pool was grown to prepare a cell bank, which was stored in liquid nitrogen. Protein expression in the stable pool proceeded in a similar manner to transient expression by thawing the cell bank vials.

[0100] To improve the processing of the linker connecting the heavy and light chains of the fXa derivative, a second polynucleotide sequence encoding human furin protein was simultaneously transfected into specific samples. The furin construct was introduced using separate vectors. For stable cell production, a stable cell pool was initially selected using pcDNA3.3 containing the fXa derivative and G-418 (0-1500 μg / mL) to generate a stable pool (parent pool). The parent pool was further transfected with a second vector containing furin (supertransfection). The supertransfected pool was further selected using antibiotics and prepared for cell banking.

[0101] Protein expression levels in cell culture were measured by ELISA (FX-EIA, Enzyme Research Laboratories) and characterized by Western blotting using monoclonal antibodies against FX / FXa heavy and light chains. An edexanet was used to create a standard curve. Proteins in the collected cell culture medium were purified by an affinity-based method using STI resin to capture functional proteins.

[0102] Example 2. Testing of expression level and activity This example tested the expression level and activity of the fXa derivative prepared in Example 1.

[0103] The expression and functional activity of andexanet (AnXa) precursors (SEQ ID NO: 4) and C01-C03 were tested in transient transfection (simultaneous transfection with furin). The conditions included chemical transfection with expifectamine, followed by the addition of enhancer and feed after 24 hours at 37°C, 8% CO2, and 135 rpm. The results are shown in the table below.

[0104] [Table A]

[0105] A stable pool of these constructs was generated. The total cell culture volume was 30 mL. Cells were passaged every 3 days until the cells fully recovered to a viability of >97%. The conditions for titer were as follows: 32°C, 5% CO2, 135 rpm; feed added on days 1, 4, 7, and 10. The results are shown in the table below.

[0106] [Table B]

[0107] The table below shows the test results when cells were further transfected with furin.

[0108] [Table C]

[0109] The results showed that C01 exhibited low levels of expression in transient and stable expression, while C02 and C03 functioned similarly to the andexanet precursors. Therefore, truncation of the 13th or 15th C-terminal residue from the heavy chain did not affect protein expression or activity, but deletion of the 20th terminal residue had a significant adverse effect.

[0110] Compared to C01-C03, C04-C11 further contained either factor X activating peptide (AP) or human serum albumin (HSA). Upon activation of wild-type factor X, AP was removed. In the production of the undexanet, AP was not part of the construct. As shown in the results below, AP inclusion significantly increased protein expression. Furthermore, when AP was fused to the C-terminus of the heavy chain (as opposed to the light chain), the construct yielded the most functionally active product (C08 and C09). Fusion to HSA was also useful in increasing expression and activity, although the effect was not as pronounced compared to AP.

[0111] [Table D]

[0112] [Table E]

[0113] Based on the above results, C05, C07, C08, and C10 were further investigated for their expression and functional activity. As shown in Figures 2A-2D, simultaneous transfection of the constructs with furin promoted an increase in the titer of functional proteins in most cases. However, among C05, C07, C08, and C10, only C08 maintained both high expression levels and functional activity.

[0114] Furthermore, as shown in the table below, simultaneous transfection of CO8 with 5% furin resulted in the highest picograms / cell / day (PCD) of approximately 1.9 in both ELISA and functional quantitative analysis calculations.

[0115] [Table F]

[0116] Example 3. Preparation and testing of additional structures Based on the test results in Example 2, this example prepared and tested a few additional constructs that provide the sequences shown in the table below.

[0117] [Table 21]

[0118] [Table 22]

[0119] [Table 23]

[0120] The domain structures of these constructs are also shown in Figure 1. Compared to C08, C12 has an intact heavy chain and an additional AP inserted between EGF2 and the heavy chain. C13 is similar to C10 but has a light chain with a truncated N-terminus. Finally, C14 contains both an N-terminal HSA (like C14) and a C-terminal AP (like C08).

[0121] The expression levels and activity of these constructs were measured together with andexanet precursor (AnXa), C10, and C12 as controls. The results are shown in the table below and plotted in Figure 3.

[0122] [Table G]

[0123] C13, which has an HSA directly fused to the EGF1 domain of the light chain, and C14, which further contains an AP domain at the C-terminus of the heavy chain, exhibited the highest expression and activity. Interestingly, the only difference between C10 and C13 was that C10 further contained specific amino acids (A1-K11) derived from the Gla-domain, but the expression of C10 was significantly lower, suggesting that direct fusion between the HSA and the EGF1 domain is beneficial. Furthermore, the results for C12 suggest that adding an additional AP between the light and heavy chains is not necessary.

[0124] This embodiment further demonstrates the benefits of fusing an HSA to the N-terminus of the light chain and an AP domain to the C-terminus of the heavy chain in the construct.

[0125] Example 4. Preparation and testing of Fc fusion product This example tested Fc fragments and fusions between Fc fragments and factor Xa derivatives such as andexanet.

[0126] The two fusion constructs were prepared as shown in Tables 25 and 26 and contained the Fc fragment from Table 24 and two different signal peptides.

[0127] [Table 24]

[0128] [Table 25]

[0129] [Table 26]

[0130] The expression of these constructs was tested in transient transfection. Conditions included chemical transfection with expifectamine, followed 24 hours later by the addition of enhancer and feed at 37°C, 8% CO2, and 135 rpm. As shown in the results below, the fXa signal peptide (construct F01) promoted increased expression of the fusion protein.

[0131] [Table H]

[0132] Although the present invention has been described in conjunction with the embodiments described above, it should be understood that the foregoing description and examples are illustrative of the present invention and are not intended to limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be obvious to those skilled in the art.

Claims

1. A protein, LC-L1-HC-L2-AP (I) (In the formula, the LC comprises the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13; L1 is a peptide linker containing a protease recognition site; the HC comprises the amino acid sequence of SEQ ID NO:11 or a peptide having at least 85% sequence identity to SEQ ID NO:11; L2 is absent or is a peptide linker that cannot be processed by proteases, and AP comprises an activation peptide wherein when said L1 is processed by said protease, it is capable of producing a two-chain polypeptide comprising said LC and said HC on separate chains, and said two-chain polypeptide is capable of binding to a factor Xa inhibitor.

2. The protein of claim 1 , wherein the protease is furin.

3. The protein of claim 2 , wherein L1 comprises the amino acid sequence of RKR or RKRRKR (SEQ ID NO: 7).

4. The protein of any one of claims 1 to 3, wherein L2 is 0 to 50 amino acid residues in length.

5. The protein of claim 4, wherein at least 50% of the amino acid residues of L2 are Gly or Ser.

6. The protein of any one of claims 1 to 5, wherein the activation peptide comprises a glycosylation site.

7. 6. The protein of claim 1, wherein the activation peptide is an activation peptide of factor IX, factor X, factor XIII, factor II, or protein C, or has at least 85% sequence identity to an activation peptide of factor IX, factor X, factor XIII, factor II, or protein C.

8. 6. The protein of any one of claims 1 to 5, wherein the activation peptide comprises the amino acid sequence of SEQ ID NO: 12, 31, 32, 33, 39 or 40, or an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 12, 31, 32, 33, 39 or 40.

9. The protein according to any one of claims 1 to 8, further comprising human serum albumin (HSA) on the N-terminal side of the LC.

10. The protein of claim 9, wherein the HSA comprises the amino acid sequence of SEQ ID NO:

15.

11. The protein of claim 9, wherein the LC does not contain amino acid residues 1 to 45 of SEQ ID NO:

2.

12. 12. The protein of any one of claims 1 to 11, wherein the produced two-chain polypeptide has a reduced ability to assemble into the prothrombin complex compared to wild-type fXa.

13. The protein according to any one of claims 1 to 12, which does not contain amino acid residues 6 to 39 of SEQ ID NO:

2.

14. The protein of claim 13 , wherein the LC comprises the amino acid sequence of SEQ ID NO: 6 or an amino acid sequence having at least 85% sequence identity to SEQ ID NO:

6.

15. The protein of any one of claims 1 to 14, wherein the produced two-chain polypeptide has reduced catalytic activity compared to wild-type human Factor Xa.

16. The protein of any one of claims 1 to 15, wherein the HC comprises the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence having at least 85% sequence identity to SEQ ID NO:

10.

17. The protein of any one of claims 1 to 16, wherein the HC comprises the amino acid sequence of SEQ ID NO:

11.

18. The protein of any one of claims 1 to 17, which does not contain amino acid residues 436 to 448 of SEQ ID NO:

2.

19. The protein of any one of claims 1 to 18, which does not contain amino acid residues 434 to 448 of SEQ ID NO:

2.

20. A protein, HSA-L2-LC-L1-HC (II) (In the formula, HSA is human serum albumin (HSA) or a variant having at least 85% sequence identity to said HSA; L1 is a peptide linker containing a protease recognition site; L2 is absent or is a peptide linker that cannot be processed by proteases; The LC comprises the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13; and The HC comprises the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity to SEQ ID NO:

11. wherein said L1 is capable of producing a two-chain polypeptide comprising said LC and said HC on separate chains when said L1 is processed by said protease, said two-chain polypeptide being capable of binding to a factor Xa inhibitor.

21. The protein of claim 20, wherein the HSA comprises the amino acid sequence of SEQ ID NO:

15.

22. The protein of claim 20, wherein the LC does not include amino acid residues 1 to 45 of SEQ ID NO:

2.

23. 23. The protein of claim 22, wherein L2 is absent.

24. 24. The protein of claim 22 or 23, wherein the protease is furin.

25. 25. The protein of claim 24, wherein L1 comprises the amino acid sequence of RKR or RKRRKR (SEQ ID NO: 7).

26. The protein of any one of claims 20 to 25, further comprising an activation peptide (AP) fused to the C-terminus of the HC.

27. 27. The protein of claim 26, wherein the activation peptide comprises a glycosylation site.

28. 28. The protein of claim 26 or 27, wherein the activation peptide is an activation peptide of factor IX, factor X, factor XIII, factor II or protein C, or has at least 85% sequence identity to an activation peptide of factor IX, factor X, factor XIII, factor II or protein C.

29. 29. The protein of claim 28, wherein the activation peptide comprises the amino acid sequence of SEQ ID NO: 12, 31, 32, 33, 39, or 40, or an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 12, 31, 32, 33, 39, or 40.

30. 30. The protein of any one of claims 20 to 29, wherein the LC comprises the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence having at least 85% sequence identity to SEQ ID NO:

13.

31. The protein of any one of claims 20 to 30, wherein the produced two-chain polypeptide has reduced catalytic activity compared to wild-type human Factor Xa.

32. 32. The protein of claim 31 , wherein the HC comprises the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence having at least 85% sequence identity to SEQ ID NO:

10.

33. The protein of claim 32, wherein the HC comprises the amino acid sequence of SEQ ID NO:

11.

34. 34. The protein of any one of claims 1 to 33, further comprising a signal or signal / propeptide.

35. The protein of claim 34, wherein the signal or signal / propeptide is selected from the group consisting of SEQ ID NOs: 34 to 37.

36. A protein comprising the amino acid sequence of SEQ ID NO:

25.

37. A protein comprising the amino acid sequence of SEQ ID NO:

26.

38. A protein comprising the amino acid sequence of SEQ ID NO:

42.

39. A protein comprising the amino acid sequence of SEQ ID NO:

43.

40. A polynucleotide encoding the protein of any one of claims 1 to 39.

41. A cell comprising the polynucleotide of claim 40.

42. 42. The cell of claim 41, further comprising a polynucleotide encoding the protease.

43. 43. A method for preparing a protein, comprising culturing the cell of claim 41 or 42 and recovering the di-chain protein from the culture.

44. 1. A two-chain polypeptide comprising: a light chain comprising the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13; and a heavy chain comprising a first fragment comprising the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity to SEQ ID NO: 11, and a second fragment C-terminal to the first fragment and comprising an activation peptide, wherein the two-chain polypeptide is capable of binding to a factor Xa inhibitor.

45. 1. A two-chain polypeptide comprising: a light chain comprising a first fragment comprising human serum albumin (HSA) or a variant thereof having at least 85% sequence identity to said HSA; and a second fragment comprising the amino acid sequence of SEQ ID NO: 13 or a peptide having at least 85% sequence identity to SEQ ID NO: 13; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 11 or a peptide having at least 85% sequence identity to SEQ ID NO: 11, wherein the two-chain polypeptide is capable of binding to a factor Xa inhibitor, and wherein the light chain does not comprise amino acid residues 1 to 45 of SEQ ID NO:

2.

46. A double-chain polypeptide obtainable by treating the protein according to any one of claims 1 to 39 with said protease.

Images